Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Maravai LifeSciences (NASDAQ:MRVI) but lowered the price target from $27 to $12.
August 09, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Maravai LifeSciences but lowered the price target from $27 to $12.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a short-term negative impact on Maravai LifeSciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100